<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RABEPRAZOLE SODIUM</span><br/>(rab-e-pra'zole)<br/><span class="topboxtradename">AcipHex<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">proton pump inhibitor</span><br/><b>Prototype: </b>Omeprazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Gastric proton pump inhibitor that specifically suppresses gastric acid secretion by inhibiting the H<sup>+</sup>, K<sup>+</sup>-ATPase enzyme system [the acid (proton H<sup>+</sup>) pump] in the parietal cells of the stomach.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by a negative urea breath test for <i>H. pylori</i> with preexisting gastric ulcer; also by elimination of S&amp;S with GERD or peptic ulcers. Produces an antisecretory effect on
         the hydrogen ion (H<sup>+</sup>) in the parietal cells. It does not exhibit H<sub>2</sub>-histamine receptor antagonist properties.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Healing and maintenance of healing of erosive or ulcerative gastroesophageal reflux disease (GERD); healing of duodenal ulcers;
         treatment of hypersecretory conditions.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to rabeprazole, lansoprazole, or omeprazole or proton pump inhibitors (PPIs) hypersensitivity; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B); severe hepatic impairment; mild to moderate hepatic disease; Japanese. Safety &amp; efficacy in children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Healing of Erosive GERD</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg q.d. <small>x</small> 48 wk, may continue up to 16 wk if needed<br/><br/><span class="indicationtitle">Maintenance Therapy for GERD</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg q.d.<br/><br/><span class="indicationtitle">Healing Duodenal Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 20 mg q.d. <small>x</small> 4 wk<br/><br/><span class="indicationtitle">Hypersecretory Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg q.d. in 12 divided doses (max: 100 mg q.d. or 60 mg b.i.d.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Adjust dose as needed with preexisting liver disease.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Headache. <span class="typehead">Skin:</span> (Rare) <span class="speceff-life">Stevens-Johnson syndrome, </span>
<span class="speceff-life">toxic epidermal necrolysis, </span>
<span class="speceff-life">erythema multiforme</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<b>Rabeprazole sodium</b> may decrease absorption of <b>ketoconazole</b>; may increase <b>digoxin</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 52% bioavailability. <span class="typehead">Distribution:</span> 96% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A and CYP2C19. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 12 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Routine serum chemistry; serum gastrin in long-term therapy.</li>
<li>Coadministered drugs: Monitor for changes in digoxin blood level.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report diarrhea, skin rash, other bothersome adverse effects to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>